Vincerx Pharma Yönetim

Yönetim kriter kontrolleri 4/4

Vincerx Pharma CEO'su Ahmed Hamdy, Dec2020 tarihinde atandı, in görev süresi 3.92 yıldır. in toplam yıllık tazminatı $ 734.95K olup, şirket hissesi ve opsiyonları dahil olmak üzere 65.2% maaş ve 34.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 5.11% ine doğrudan sahiptir ve bu hisseler $ 437.31K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.5 yıl ve 3.8 yıldır.

Anahtar bilgiler

Ahmed Hamdy

İcra Kurulu Başkanı

US$735.0k

Toplam tazminat

CEO maaş yüzdesi	65.2%
CEO görev süresi	3.9yrs
CEO sahipliği	5.1%
Yönetim ortalama görev süresi	3.5yrs
Yönetim Kurulu ortalama görev süresi	3.8yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Ahmed Hamdy'un ücretlendirmesi Vincerx Pharma'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$27m
Jun 30 2024	n/a	n/a	-US$28m
Mar 31 2024	n/a	n/a	-US$38m
Dec 31 2023	US$735k	US$479k	-US$40m
Sep 30 2023	n/a	n/a	-US$46m
Jun 30 2023	n/a	n/a	-US$54m
Mar 31 2023	n/a	n/a	-US$61m
Dec 31 2022	US$1m	US$460k	-US$63m
Sep 30 2022	n/a	n/a	-US$58m
Jun 30 2022	n/a	n/a	-US$66m
Mar 31 2022	n/a	n/a	-US$49m
Dec 31 2021	US$615k	US$460k	-US$39m
Sep 30 2021	n/a	n/a	-US$49m
Jun 30 2021	n/a	n/a	-US$25m
Mar 31 2021	n/a	n/a	-US$23m
Dec 31 2020	US$622k	US$15k	-US$17m

Tazminat ve Piyasa: Ahmed 'ın toplam tazminatı ($USD 734.95K ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 646.00K ).

Tazminat ve Kazançlar: Ahmed 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Ahmed Hamdy (59 yo)

3.9yrs

Görev süresi

US$734,953

Tazminat

Dr. Ahmed M. Hamdy, M.D., is Co-Founder of Vincerx Pharma, Inc. (formerly known as Vincera Pharma, Inc.) and has been its Chief Executive Officer and Chairman of the Board since December 2020. He served as...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ahmed Hamdy	Co-Founder	3.9yrs	US$734.95k	5.11% $ 437.3k
Raquel Izumi	Co-Founder	3.9yrs	US$668.96k	0.26% $ 22.0k
Alexander Seelenberger	Chief Financial Officer	3.9yrs	US$565.67k	0.099% $ 8.5k
Tom Thomas	Founder	3.7yrs	US$3.16m	Veri yok
John Byrd	Founder & Chairman of Scientific Advisory Board	no data	Veri yok	4.82% $ 412.8k
Hans-Georg Lerchen	Chief Scientific Officer	3.7yrs	Veri yok	Veri yok
Gabriela Jairala	Vice President of Investor Relations & Corporate Communications and Chief of Staff	1.3yrs	Veri yok	Veri yok
Karen Quarford	Vice President of Quality Operations & Compliance	1.8yrs	Veri yok	Veri yok
Melissa Merrick	Senior Director of People & Culture and Head of Human Resource	3.3yrs	Veri yok	Veri yok
Beatrix Stelte-Ludwig	Executive Chief Development Officer	3.5yrs	Veri yok	Veri yok
Steven Bloom	Chief Business Officer	1.4yrs	Veri yok	Veri yok
Raj Dua	VP of Biologics Development and Manufacturing and Sr. VP of Chemistry & Manufacturing	1.4yrs	Veri yok	Veri yok

3.5yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim: VINC 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ahmed Hamdy	Co-Founder	3.9yrs	US$734.95k	5.11% $ 437.3k
Raquel Izumi	Co-Founder	3.9yrs	US$668.96k	0.26% $ 22.0k
John Byrd	Founder & Chairman of Scientific Advisory Board	3.6yrs	Veri yok	4.82% $ 412.8k
Francisco Salva	Independent Director	3.9yrs	US$69.14k	0% $ 0
Brian Druker	Independent Director	3.9yrs	US$47.89k	0.16% $ 14.0k
Anthony Tolcher	Member of Scientific Advisory Board	3.6yrs	Veri yok	Veri yok
Laura Bushnell	Independent Director	3.9yrs	US$52.89k	0.057% $ 4.9k
Ruth Stevens	Independent Director	3.5yrs	US$47.89k	0% $ 0
Howard Burris	Member of Scientific Advisory Board	3.6yrs	Veri yok	Veri yok
Ian Flinn	Member of Scientific Advisory Board	3.6yrs	Veri yok	Veri yok
Andre Goy	Member of Scientific Advisory Board	3.6yrs	Veri yok	Veri yok
John Lee	Independent Director	3.9yrs	US$47.89k	0.0024% $ 203.7

3.8yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: VINC 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.8 yıldır).

Vincerx Pharma Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insufficient new directors

Vincerx Pharma, Inc., Annual General Meeting, May 23, 2024

Vincerx Pharma, Inc. Announces Resignation of Board of Directors

High number of new and inexperienced directors

Founder recently bought US$56k worth of stock

Vincerx Pharma, Inc. Announces Departure of Hermes Garban as Chief Medical Officer, Effective on or Before August 6, 2022

Recent updates

Vincerx Pharma, Inc. Receives Extension from Nasdaq Stock Market LLC to Meet the Exchange's Minimum Bid Price Requirement

New major risk - Shareholder dilution

New major risk - Market cap size

Price target decreased by 14% to US$6.00

Vincerx Pharma, Inc. Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline

Here's Why Vincerx Pharma (NASDAQ:VINC) Must Use Its Cash Wisely

New major risk - Financial position

Insufficient new directors

New major risk - Negative shareholders equity

New minor risk - Shareholder dilution

Vincerx Pharma, Inc. has completed a Follow-on Equity Offering.

Vincerx Pharma, Inc. has filed a Follow-on Equity Offering.

Vincerx Pharma, Inc., Annual General Meeting, May 23, 2024

New minor risk - Market cap size

Vincerx Pharma, Inc. Presents Positive Preliminary Phase 1 Data for Vip236 and Updates on Pipeline Progress At the American Association for Cancer Research (Aacr) Annual Meeting 2024

Vincerx Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Vincerx Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Price target increased by 35% to US$9.00

New major risk - Share price stability

Vincerx Pharma, Inc. Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma

New major risk - Financial position

New major risk - Revenue and earnings growth

Vincerx Pharma Receives Non-Compliance Notice from the Nasdaq Stock Market

Vincerx Pharma Receives Non-Compliance Notice from the Nasdaq Stock Market

Vincerx Pharma, Inc. Announces FDA Clearance of IND for VIP943

Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?

New major risk - Financial position

Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?

Vincerx Pharma, Inc. Announces Resignation of Board of Directors

Vincerx Pharma Announces Fda Safe to Proceed Letter for Investigational New Drug (Ind) Application for Its <Alpha>V<Beta>3 Small Molecule-Drug Conjugate (Smdc) Vip236

Price target decreased to US$8.40

Vincerx Pharma, Inc. Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022

Price target decreased to US$12.60

High number of new and inexperienced directors

Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?

Founder recently bought US$56k worth of stock

Vincerx Pharma, Inc.(NasdaqCM:VINC) dropped from Russell 2000 Growth Index

Is Vincerx Pharma (NASDAQ:VINC) In A Good Position To Invest In Growth?

Vincerx Pharma Presents Preclinical and Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Lymphoma at the European Hematology Association 2022 Congress

Vincerx Pharma, Inc. Announces Departure of Hermes Garban as Chief Medical Officer, Effective on or Before August 6, 2022

Vincerx Pharma, Inc. Provides Clinical Updates

Price target decreased to US$21.33

High number of new and inexperienced directors

Vincerx, Inc., Annual General Meeting, May 26, 2022

Price target decreased to US$23.86

Price target decreased to US$26.57

High number of new and inexperienced directors

Founder recently bought US$65k worth of stock

Vincerx Pharma, Inc. Announces First Patient Dosed in Phase 1 Dose-Escalation Study of VIP152 in Relapsed or Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

Vincerx Pharma Presents Data on PTEFb/CDK9 Inhibitor VIP152 in DLBCL and CLL at the 63rd American Society of Hematology Annual Meeting

Vincerx Pharma Receives Orphan Drug Designation from European Commission for VIP152 for the Treatment of Diffuse Large B-Cell Lymphoma

Independent Director recently bought US$126k worth of stock

Vincerx Pharma Presents Clinical Data on VIP512, its PTEFb/CDK9 Inhibitor, in Patients with Double-Hit Lymphoma at ASCO 2021

Vincerx Pharma Announces First Patient Dosed in Phase 1b Study of VIP152 in MYC-Driven Relapsed or Refractory Aggressive Lymphomas and Advanced Solid Tumors

Vincerx Pharma doses first patient in early-stage VIP152 cancer study

Independent Director has left the company

Vincerx Pharma, Inc. Announces Management Appointments

Vincerx Pharma, Inc., Annual General Meeting, May 13, 2021

Vincerx, Inc. Announces Executive Changes

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş